Source:http://linkedlifedata.com/resource/pubmed/id/18791166
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
12
|
| pubmed:dateCreated |
2008-11-25
|
| pubmed:abstractText |
We sought to determine whether thrombophilic defects increase recurrent venous thromboembolism (VTE) during warfarin therapy. Six hundred sixty-one patients with unprovoked VTE who were randomized to extended low-intensity (international normalized ratio [INR], 1.5-1.9) or conventional-intensity (INR, 2.0-3.0) anticoagulant therapy were tested for thrombophilia and followed for a mean of 2.3 years. One or more thrombophilic defects were present in 42% of patients. The overall rate of recurrent VTE was 0.9% per patient-year. Recurrent VTE was not increased in the presence of factor V Leiden (hazard ratio [HR], 0.7; 95% CI, 0.2-2.6); the 20210G>A prothrombin gene mutation (HR, 0); antithrombin deficiency (HR, 0); elevated factor VIII (HR, 0.7; 95% CI, 0.1-5.4); elevated factor XI (HR, 0.7; 95% CI, 0.1-5.0), or elevated homocysteine (HR, 0.7; 95% CI, 0.1-5.3), but showed a trend to an increase with an antiphospholipid antibody (HR, 2.9; 95% CI, 0.8-10.5). Compared with patients with no thrombophilic defects, the rate of recurrence was not increased in the presence of one (HR, 0.7; 95% CI, 0.2-2.3) or more than one (HR, 0.7; 95% CI, 0.2-3.4) defect. We conclude that single or multiple thrombophilic defects are not associated with a higher risk of recurrent VTE during warfarin therapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
1528-0020
|
| pubmed:author |
pubmed-author:AndersonDavid RDR,
pubmed-author:CrowtherMark AMA,
pubmed-author:DemersChristineC,
pubmed-author:DolanSeanS,
pubmed-author:ELATE Investigators,
pubmed-author:GeertsWilliamW,
pubmed-author:GentMichaelM,
pubmed-author:GinsbergJeffrey SJS,
pubmed-author:HambletonJulieJ,
pubmed-author:JulianJim AJA,
pubmed-author:KahnSusan RSR,
pubmed-author:KassisJeannineJ,
pubmed-author:KearonCliveC,
pubmed-author:KovacsMichael JMJ,
pubmed-author:MackinnonBetsyB,
pubmed-author:RodgerMarcM,
pubmed-author:SolymossSusanS,
pubmed-author:TurpieAlexander GAG,
pubmed-author:WeitzJeffrey IJI,
pubmed-author:WellsPhilipP,
pubmed-author:van NguyenPaulP
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
1
|
| pubmed:volume |
112
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
4432-6
|
| pubmed:meshHeading |
pubmed-meshheading:18791166-Adult,
pubmed-meshheading:18791166-Aged,
pubmed-meshheading:18791166-Anticoagulants,
pubmed-meshheading:18791166-Dose-Response Relationship, Drug,
pubmed-meshheading:18791166-Double-Blind Method,
pubmed-meshheading:18791166-Factor V,
pubmed-meshheading:18791166-Female,
pubmed-meshheading:18791166-Genetic Predisposition to Disease,
pubmed-meshheading:18791166-Humans,
pubmed-meshheading:18791166-Male,
pubmed-meshheading:18791166-Middle Aged,
pubmed-meshheading:18791166-Recurrence,
pubmed-meshheading:18791166-Risk Factors,
pubmed-meshheading:18791166-Thrombophilia,
pubmed-meshheading:18791166-Treatment Outcome,
pubmed-meshheading:18791166-Venous Thromboembolism,
pubmed-meshheading:18791166-Warfarin
|
| pubmed:year |
2008
|
| pubmed:articleTitle |
Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial.
|
| pubmed:affiliation |
McMaster University, Hamilton, ON. kearonc@mcmaster.ca
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|